

# CARDIO-ONCOLOGY

## LANDMARK TRIALS · GUIDELINE · POSITION STATEMENTS

### Guideline and Position Statements

1. Armenian SH, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017 Mar 10; 35(8):893-911. PMID 27918725
2. Bloom MW, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging. *Circ Heart Fail*. 2016; 9(1):e002661. PMID: 26747861
3. Campi U, et al. Cardio-Oncology: vascular and metabolic perspectives: A Scientific Statement from the American Heart Association. *Circulation*. 2019 Mar 26; 139(13):e579-e602. PMID: 30786722
4. Curigliano G, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents, and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct; 23 Suppl 7:vii155-66. PMID: 22997448
5. Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020 Feb; 31(2):171-190. PMID: 31959335
6. Desai MY, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2019 Aug 20; 74(7):905-927. PMID: 31416535
7. Gilchrist SC, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation*. 2019 May 21; 139(21):e997-e1012. PMID: 30955352
8. Hamo CE, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 2: prevention, treatment, guidelines, and future directions. *Circ Heart Fail*. 2016 Feb; 9(2):e002843. PMID: 26839395
9. Iliescu C, et al. SCAI expert consensus: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). *Catheter Cardiovasc Interv*. 2016 Apr; 87(5):E202-223. PMID: 26756277
10. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2020;38(5):496- 520. PMID: 31381464
11. Lancellotti P, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2013 Sep; 26(9):1013-1032. PMID: 23998694
12. Maurer MS, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019 Sep; 12(9):e006075. PMID: 31480867

13. Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014 Sep; 27(9):911-939. PMID: 25172399
14. Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016 Sept 21; 37(36):2768-2801. PMID: 27567406

## General Topics in Cardio-Oncology

1. Bonsu JM, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. *J Am Coll Cardiol*. 2020 Feb 18; 75(6):620-628. PMID: 32057377
2. Hayek SS, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 May 7; 73(17):2226-2235. PMID: 31047011
3. Jones DN, et al. Frequency of transition from stage A to stage B heart failure after initiating potentially cardiotoxic chemotherapy. *JACC Heart Fail*. 2018 Dec; 6(12):1023-1032. PMID: 30414819
4. Kappel C, et al. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. *Curr Oncol*. 2019 Jun; 26(3):e322-e327. PMID: 31285675
5. Koene RJ, et al. Shared risk factors in cardiovascular disease and cancer. *Circulation*. 2016 Mar 15; 133(11):1104-14. PMID: 26976915
6. Lopez-Sendon J, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. *Eur Heart J*. 2020 Feb 4. pii: ehaa006. PMID: 32016393
7. Pfeffer TJ, et al. Increased cancer prevalence in peripartum cardiomyopathy. *JACC: CardioOncology*. 2019 Dec; 1(2). DOI: 10.1016/j.jacc.2019.09.008
8. Takahashi I, Cologne J, Haruta D, et al. Association Between Prevalence of Peripheral Artery Disease and Radiation Exposure in the Atomic Bomb Survivors. *J Am Heart Assoc*. 2018;7(23):e008921. PMID: 30486720

## Survivorship

1. Armenian SH, et al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. *J Clin Oncol*. 2018 Jul 20; 36(21):2135-2144. PMID: 29874141
2. Armenian SH, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. *Cancer*. 2018 Feb 15; 124(4):850-857. PMID: 29112235
3. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. *J Clin Oncol*. 2013 Oct 10;31(29):3673-80. doi: 10.1200/JCO.2013.49.3205. Epub 2013 Sep 3. PMID: 24002505; PMCID: PMC3804290.

4. Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, Border WL, Feijen EA, Green DM, Meacham LR, Meeske KA, Mulrooney DA, Ness KK, Oeffinger KC, Sklar CA, Stovall M, van der Pal HJ, Weathers RE, Robison LL, Yasui Y. Individual prediction of heart failure among childhood cancer survivors. *J Clin Oncol*. 2015 Feb 10;33(5):394-402. doi: 10.1200/JCO.2014.56.1373. Epub 2014 Oct 6. PMID: 25287823; PMCID: PMC4314592.
5. Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A. Abnormal exercise response in long-term survivors of Hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. *J Am Coll Cardiol*. 2015 Feb 17;65(6):573-83. doi: 10.1016/j.jacc.2014.11.035. PMID: 25677317.
6. Mulrooney DA, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. *BMJ*. 2020 Jan 15; 368:I6794. PMID: 31941657
7. Scott JM, et al. Association of exercise with mortality in adult survivors of childhood cancer. *JAMA Oncol*. 2018 Oct 1; 4(10):1352-1358. PMID: 29862412
8. Takx RAP, Vliegenthart R, Schoepf UJ, Pilz LR, Schoenberg SO, Morris PB, Henzler T, Apfaltrer P. Coronary artery calcium in breast cancer survivors after radiation therapy. *Int J Cardiovasc Imaging*. 2017 Sep;33(9):1425-1431. doi: 10.1007/s10554-017-1119-x. Epub 2017 Mar 24. PMID: 28342038.
9. Tjessem KH, Bosse G, Fosså K, Reinertsen KV, Fosså SD, Johansen S, Fosså A. Coronary calcium score in 12-year breast cancer survivors after adjuvant radiotherapy with low to moderate heart exposure - Relationship to cardiac radiation dose and cardiovascular risk factors. *Radiother Oncol*. 2015 Mar;114(3):328-34. doi: 10.1016/j.radonc.2015.01.006. Epub 2015 Jan 16. PMID: 25600105.

## **Radiation Therapy and Radiation-Induced Heart Disease**

1. Addison D, et al. Incidental statin use and the risk of stroke or transient ischemic attack after radiotherapy for head and neck cancer. *J Stroke*. 2018 Jan; 20(1):71-79. PMID: 29402065
2. Atkins KM, Rawal B, Chaunzwa TL, et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. *J Am Coll Cardiol*. 2019;73(23):2976- 2987. PMID: 31196455
3. Bendary A, Ramzy A, Bendary M, Salem M. Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis. *Open Heart*. 2020 Mar 11;7(1):e001131. doi: 10.1136/openhrt-2019-001131. PMID: 32201582; PMCID: PMC7066604.
4. Bijl JM, et al. Assessment of valvular disorders in survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy ± chemotherapy. *Am J Cardiol*. 2016 Feb 15; 117(4):691-696. PMID: 26772441
5. Boulet J, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. *J Am Heart Assoc*. 2019 Jul 2; 8(13):e005996. PMID: 31213106
6. Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013 Mar 14; 368(11):987-998. PMID: 23484825

7. Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-Associated Cardiac Disease: A Practical Approach to Diagnosis and Management. *JACC Cardiovasc Imaging*. 2018 Aug;11(8):1132-1149. doi: 10.1016/j.jcmg.2018.04.028. PMID: 30092970.
8. Desai MY, Windecker S, Lancellotti P, Bax JJ, Griffin BP, Cahlon O, Johnston DR. Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2019 Aug 20;74(7):905-927. doi: 10.1016/j.jacc.2019.07.006. PMID: 31416535.
9. Desai MY, Wu W, Masri A, Popovic ZB, Agarwal S, Smedira NG, Lytle BW, Griffin BP. Increased aorto-mitral curtain thickness independently predicts mortality in patients with radiation-associated cardiac disease undergoing cardiac surgery. *Ann Thorac Surg*. 2014 Apr;97(4):1348-55. doi: 10.1016/j.athoracsur.2013.12.029. Epub 2014 Feb 22. PMID: 24565403.
10. Groarke JD, et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. *Eur Heart J*. 2014 Mar; 35(10):612-623. PMID: 23666251
11. Guha A, Dey AK, Arora S, Cavender MA, Vavalle JP, Sabik JF III, Jimenez E, Jneid H, Addison D. Contemporary Trends and Outcomes of Percutaneous and Surgical Aortic Valve Replacement in Patients With Cancer. *J Am Heart Assoc*. 2020 Jan 21;9(2):e014248. doi: 10.1161/JAHA.119.014248. Epub 2020 Jan 21. PMID: 31960751; PMCID: PMC7033818.
12. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. *J Am Coll Cardiol*. 2003 Aug 20;42(4):743-9. doi: 10.1016/s0735-1097(03)00759-9. PMID: 12932613.
13. Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. *Catheter Cardiovasc Interv*. 2008;72(4):563- 568. PMID: 18819153
14. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, Jubran A, Yoon SH, Makkar RR, Taramasso M, Russo M, Maisano F, Sinning JM, Shamekhi J, Biasco L, Pedrazzini G, Moccetti M, Latib A, Pagnesi M, Colombo A, Tamburino C, D' Arrigo P, Windecker S, Pilgrim T, Tchetché D, De Biase C, Guerrero M, Iftikhar O, Bosmans J, Bedzra E, Dvir D, Mylotte D, Sievert H, Watanabe Y, Søndergaard L, Dagnegård H, Codner P, Kodali S, Leon M, Kornowski R. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. *JACC Cardiovasc Interv*. 2019 Jan 14;12(1):78-86. doi: 10.1016/j.jcin.2018.10.026. PMID: 30621982.
15. Saiki H, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. *Circulation*. 2017 Apr 11; 135(15):1388-1396. PMID: 28132957
16. Viswanathan AN, Lee LJ, Eswara JR, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. *Cancer*. 2014;120(24):3870- 3883. PMID: 25056522
17. Zhang D, Guo W, Al-Hijji MA, El Sabbagh A, Lewis BR, Greason K, Sandhu GS, Eleid MF, Holmes DR, Herrmann J. Outcomes of Patients With Severe Symptomatic Aortic Valve Stenosis After Chest Radiation:

Transcatheter Versus Surgical Aortic Valve Replacement. *J Am Heart Assoc.* 2019 May 21;8(10):e012110. doi: 10.1161/JAHA.119.012110. PMID: 31124737; PMCID: PMC6585322.

## Amyloidosis and Multiple Myeloma

1. Barrett CD, et al. A changing landscape of mortality for systemic light chain amyloidosis. *JACC Heart Fail.* 2019 Oct 5. pii: S2213-1779(19)30593-1. PMID: 31606365
2. Castaño A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J.* 2017 Oct 7; 38(38):2879-2887. PMID: 29019612
3. Cavalcante JL, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. *J Cardiovasc Magn Reson.* 2017 Dec 7; 19(1):98. PMID: 29212513
4. Chacko L, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *Eur Heart J.* 2020 Jan 17; 1-10. PMID: 31950987
5. Chari A, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. *Blood Adv.* 2018 Jul 10; 2(13):1633-1644. PMID: 29991494
6. Cornell RF, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. *J Clin Oncol.* 2019 Aug 1; 37(22):1946-1955. PMID: 31188726
7. Dungu JN, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. *JACC Cardiovas Imaging.* 2014 Feb; 7(2):133-142. PMID: 24412186
8. El-Am EA, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. *J Am Coll Cardiol.* 2019 Feb 12; 73(5):589-597. PMID: 30732713
9. Falk RH, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. *J Am Coll Cardiol.* 2016 Sep 20; 68(12):1323-1341. PMID: 27634125
10. Fradley MG, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. *Br J Haematol.* 2018 Jan; 180(2):217-275. PMID: 29048105
11. Giancaterino S, Urey MA, et al. Management of arrhythmias in cardiac amyloidosis. *J Am Coll Cardiol EP.* 2020 Apr; 6(4): 351-361. PMID: 32327068
12. Judge DP, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. *J Am Coll Cardiol.* 2019 Jul 23; 74(3):285-295. PMID: 30885685
13. Li W, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. *JAMA Oncol.* 2017 Jul 1; 3(7):980-988. PMID: 27632640
14. Li W, et al. Cardiovascular complications of novel multiple myeloma treatments. *Circulation.* 2016 Mar 1; 133(9):908-912. PMID: 26927008

15. Maurer MS, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. *Circ Heart Fail*. 2015 May; 8(3):519-526.
16. Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2018 Sep 13; 379(11):1007-1016. PMID: 30145929
17. Nitsche C, Aschauer S, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. *Eur J Heart Fail*. 2020 Feb 20. PMID: 32078212
18. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. *N Engl J Med*. 2015 Jan 1;372(1):21-9. doi: 10.1056/NEJMoa1404852. PMID: 25551524; PMCID: PMC4382209.
19. Raina S, et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. *JACC Cardiovasc Imaging*. 2016 Nov; 9(11):1267-1277. PMID: 27568115
20. Sanfilippo KM, et al. Statins Are Associated With Reduced Mortality in Multiple Myeloma. *J Clin Oncol*. 2016 Nov 20;34(33):4008-4014. PMID: 27646948
21. Scully PR, Patel KP, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. *Eur Heart J*. 2020 Apr 8:ehaa170. PMID: 32267922
22. Solomon SD, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. *Circulation*. 2019 Jan 22; 139(4):431-443. PMID: 30586695
23. Treibel TA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. *Circ Cardiovasc Imaging*. 2016 Aug; 9(8): pii: e005066. PMID: 27511979
24. Witteles RM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019 Aug; 7(8):709-716. PMID: 31302046
25. Zhang KW, et al. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. *JACC Basic Transl Sci*. 2019 Jun 24; 4(3):438-448. PMID: 31312767

## Breast Cancer

1. Calvillo-Arguelles O, et al. Trastuzumab-related cardiotoxicity and cardiac care in patients with HER2 positive metastatic breast cancer. *Am J Cardiol*. 2020 Jan 27. pii: S0002-9149(2)30070-9. PMID: 32087998
2. Curigliano G, et al. Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer. *Oncologist*. 2019 May 7. pii: theoncologist.2018-0773. PMID: 31064888
3. Ewer MS, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*. 2005 Nov 1; 23(31):7820-7826. PMID: 16258084
4. Khosrow-Khavar F, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. *Circulation*. 2020 Feb 18; 141(7):549-559. PMID: 32065766

5. Matthews A, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. *BMJ*. 2018 Oct 8;363:k3845. PMID: 30297439
6. Saiki H, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. *Circulation*. 2017 Apr 11; 135(15):1388-1396. PMID: 28132957
7. Tromp J, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. *Eur J Heart Fail*. 2020 Feb 20. PMID: 32078215

## Prostate Cancer

1. Bhatia N, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. *Circulation*. 2016 Feb 2; 133(5):537-541. PMID: 26831435
2. Deka R, Simpson DR, Panizzon MS, et al. Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy. *Prostate Cancer Prostatic Dis*. 2019;22(4):600- 608. PMID: 30988408
3. Hu JR, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. *Arterioscler Thromb Vasc Biol*. 2020 Mar; 40(3):e55-e64. PMID: 31969015
4. Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, Folsom AR, Han M, Platz EA. Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study. *Cancer Epidemiol Biomarkers Prev*. 2019 Mar;28(3):563-569. doi: 10.1158/1055-9965.EPI-18-0965. Epub 2018 Nov 28. PMID: 30487131; PMCID: PMC6401240.
5. Lee HH, et al. Prostate cancer in men treated with advanced heart failure: should we keep screening? *Urology*. 2020 Feb; 136:46-50. PMID: 31786304
6. Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. *J Urol*. 2020 Jun;203(6):1109-1116. doi: 10.1097/JU.0000000000000714. Epub 2020 Jan 3. PMID: 31899651.
7. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. *CA Cancer J Clin*. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2. PMID: 20124400; PMCID: PMC3049943.

8. Margel D, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. *J Urol*. 2019 Dec; 202(6):1199-1208. PMID: 31188734
9. Melloni C, Nelson A. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk. *J Cardiovasc Transl Res*. 2019 Dec 12. doi: 10.1007/s12265-019-09942-w. Epub ahead of print. PMID: 31833002.
10. O'Farell S, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. *J Clin Oncol*. 2015 Apr 10; 33(11):1243-51. PMID: 25732167

## **Gynecologic Malignancies**

1. Kitson SJ, et al. The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study. *Gynecol Oncol*. 2018 Jan; 148(1):154-160. PMID: 29174567
2. Soisson S, Ganz PA, Gaffney D, et al. Long-term cardiovascular outcomes among endometrial cancer survivors in a large, population-based cohort study. *J Natl Cancer Inst*. 2018;110(12):1342- 1351. PMID: 29741696
3. Ward KK, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. *Gynecol Oncol*. 2012 Aug; 126(2):176-179. PMID: 22507532

## **Vascular Toxicities**

1. Herrmann J. Common vascular toxicities of cancer therapies. *Cardiol Clin*. 2019 Nov; 37(4):365-384. PMID: 31587779.
2. Hermann J, et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. *Circulation*. 2016 Mar 29; 133(13):1272-1289. PMID: 27022039
3. Li W, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol*. 2015 Sep 8;66(10):1160-1178. PMID: 26337996
4. Touyz RM, et al. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. *J Am Soc Hypertens*. 2018 Jun; 12(6):409-425. PMID: 29703600

## **VTE Prophylaxis and Treatment**

1. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Suevo MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med*. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. PMID: 32223112.



2. Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. *J Thromb Haemost.* 2019 Jan; 17(1):72-76. PMID: 30450803
3. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. *N Engl J Med.* 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. PMID: 30511879.
4. Cornell RF, et al. Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory therapy. *Front Oncol.* 2019 Feb 26; 9:45. PMID: 30873378
5. Key NS, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol.* 2019 Aug 5; JCO1901461. PMID: 31381464
6. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol.* 2020;38(5):496- 520. PMID: 31381464
7. Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood.* 2008 May 15; 111(10):4902-4907. PMID: 18216292
8. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N Engl J Med.* 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. PMID: 30786186.
9. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost.* 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. PMID: 31630479.
10. Melloni C, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. *Am J Med.* 2017 Dec; 130(12):1440-1448. PMID: 28739198
11. Mosarla RC, et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2019 Mar 26; 73(11):1336-1349. PMID: 30898209
12. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. *Lancet Haematol.* 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1. PMID: 27476789.
13. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai

- VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med*. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. PMID: 29231094.
14. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). *J Clin Oncol*. 2018 Jul 10;36(20):2017-2023. doi: 10.1200/JCO.2018.78.8034. Epub 2018 May 10. PMID: 29746227.

## Cardiac Biomarkers

1. Cardinale D, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol*. 2000 Aug; 36(2):517-522. PMID: 10933366
2. Cardinale D, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. *Circulation*. 2004 Jun 8; 109(22):2749-2754. PMID: 15148277
3. Cardinale D, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *J Clin Oncol*. 2010 Sep 1; 28(25):3910-3916. PMID: 20679614
4. Demissei BG, et al. Changes in cardiovascular biomarkers with breast cancer therapy and association with cardiac dysfunction. *J Am Heart Assoc*. 2020 Jan 21; 9(2):e014708. PMID: 31959034
5. Ky B, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. *J Am Coll Cardiol*. 2014 Mar 4; 63(8):809-816. PMID: 24291281

## Anthracyclines

1. Cardinale D, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol*. 2010 Jan 19; 55(3):213-220. PMID: 20117401
2. Cardinale D, et al. Anthracycline-induced cardiotoxicity: A multicenter randomized trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur J Cancer*. 2018 May; 94:126-137. PMID: 29567630
3. Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015 Jun 2; 131(22):1981-1988. PMID: 25948538
4. Cardinale D, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation*. 2006 Dec 5; 114(23):2474-2481. PMID: 17101852

## Immune Checkpoint Inhibitors

1. Awadalla M, et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. *J Immunother Cancer*. 2019 Feb 22; 7(1):53. PMID: 30795818
2. Ball S, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 Oct 1; 74(13):1714-1727. PMID: 31558256
3. Bonaca MP, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. *Circulation*. 2019 Jul 2; 140(2):80-91. PMID: 31390169
4. Davis EJ, et al. Hematologic complications of immune checkpoint inhibitors. *Oncologist*. 2019 May; 24(5):584-588. PMID: 30819785
5. Lyon AR, et al. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol*. 2018 Sep; 19(9):e447-e458. PMID: 30191849
6. Mahmood SS, et al. Myocarditis in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol*. 2018 Apr 24; 71(16):1755-1764. PMID: 29567210
7. Moslehi JJ, et al. Fulminant myocarditis: evolving diagnosis, evolving biology, evolving prognosis. *J Am Coll Cardiol*. 2019 Jul 23; 74(3):312-314. PMID: 31319913
8. Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017 Nov 21;5(1):95. PMID: 29162153

## Ibrutinib

1. Brown JR, et al. Incidence of and risk factors for major hemorrhage in patients treated with ibrutinib: an integrated analysis. *Br J Haematol*. 2019 Feb; 184(4):558-569. PMID: 30506764
2. Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. *Leuk Lymphoma*. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. PMID: 28504030.
3. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ. Cardiovascular Toxicities Associated With Ibrutinib. *J Am Coll Cardiol*. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056. PMID: 31558250.

## Targeted Cancer Therapies

1. Anand K, et al. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). *JACC: CardioOncology*. 2019 Dec; 1(2). DOI: 10.1016/j.jacc.2019.10.006
2. Li W, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol*. 2015 Sep 8; 66(10):1160-1178. PMID: 26337996

3. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med*. 2016 Oct 13; 375(15):1457-1467. PMID: 27732808

## **BRAF and MEK Inhibitors**

1. Bronte E, et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. *Pharmacol Ther*. 2018 Dec; 192:65-73. PMID: 29964124
2. Mincu RI, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. *JAMA Netw Open*. 2019 Aug 2; 2(8): e198890. PMID: 31397860

## **Fluoropyrimidine-Associated Cardiotoxicity**

1. Ison G, et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs. *Clin Cancer Res*. 2016 Sep 15; 22(18):4545-9. PMID: 27401247
2. Kanduri J, et al. Fluoropyrimidine-associated cardiotoxicity. *Cardiol Clin*. 2019 Nov; 37(4):399-405. PMID: 31587781
3. Ma WW, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. *Cancer*. 2017 Jan 1; 123(2):345-356. PMID: 27622829
4. Sara JD, et al. 5-fluorouracil and cardiotoxicity: a review. *Ther Adv Med Oncol*. 2018 Jun 18; 10:1758835918780140. PMID: 29977352

## **Cardioprotection**

1. Acar Z, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. *J Am Coll Cardiol*. 2011 Aug 23; 58(9):988-989. PMID: 21851890
2. Akpek M, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail*. 2015 Jan; 17(1):81-89. PMID: 25410653
3. Avila MS, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. *J Am Coll Cardiol*. 2018 May 22; 71(20):2281-2290. PMID: 29540327
4. Boekhout AH, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. *JAMA Oncol*. 2016 Aug 1; 2(8):1030-1037. PMID: 27348762
5. Bosch X, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). *J Am Coll Cardiol*. 2013 Jun 11; 61(23):2355-2362. PMID: 23583763

6. Dewilde S, Carroll K, Nivelles E, Sawyer J. Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. *Cost Eff Resour Alloc*. 2020 Feb 10; 18:7. PMID: 32063753
7. Guglin M, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. *J Am Coll Cardiol*. 2019 Jun 11; 73(22):2859-2868. PMID: 31171092
8. Gulati G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J*. 2016 Jun 1; 37(21):1671-1680. PMID: 26903532
9. Lynce F, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. *Breast Cancer Res Treat*. 2019 Jun;175(3):595-603. PMID: 30852761
10. Narayan HK, et al. Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. *Open Heart*. 2019 Jun 24; 6(1):e001025. PMID: 31297226
11. Nielsen SF, et al. Statin use and reduced cancer-related mortality. *N Engl J Med*. 2012 Nov 8; 367(19):1792-1802. PMID: 23134381
12. Pituskin E, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. *J Clin Oncol*. 2017 Mar 10; 35(8):870-877. PMID: 27893331
13. Seicean S, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline therapy: an observational clinical cohort study. *J Am Coll Cardiol*. 2012 Dec 11; 60(23):2384-2390.
14. Shaikh F, et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2015 Nov 23; 108(4). pii:djv357. PMID: 26598513

## Clonal Hematopoiesis

1. Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017 Jul 13; 377(2):111-121. PMID: 28636844
2. Libby P, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 Jul 30; 74(4):567-577. PMID: 31345432

## Imaging

1. Armstrong GT, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. *J Am Coll Cardiol*. 2015 Jun 16; 65(23):2511-2522. PMID: 26065990

2. Awadalla M, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. *J Am Coll Cardiol*. 2020 Feb 11; 75(5):467-478. PMID: 32029128
3. Jordan JH, et al. Cardiovascular magnetic resonance in the oncology patient. *JACC Cardiovasc Imaging*. 2018 Aug; 11(8):1150-1172. PMID: 30092971
4. Lancellotti P, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2013 Sep; 26(9):1013-1032. PMID: 23998694
5. Plana JC, et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. *JACC Cardiovasc Imaging*. 2018 Aug; 11(8):1173-1186. PMID: 30092972
6. Thavendiranathan P, et al. Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study. *J Clin Oncol*. 2018 Oct 20; 36(30):2980-2987. PMID: 29791284
7. Walker J, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. *J Clin Oncol*. 2010 Jul 20; 28(21):3429-3436. PMID: 20530277
8. Zhang KW, et al. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. *JACC Cardiovasc Imaging*. 2018 Aug; 11(8):1059-1068. PMID: 29550306

## **Hematopoietic Stem Cell Transplantation**

1. Armenian SH, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. *Blood*. 2012 Nov 29; 120(23):4505-4512. PMID: 23034279
2. Baker JK, et al. Cardiotoxicity in hematopoietic stem cell transplant: keeping the beat. *Clin Lymphoma Myeloma Leuk*. 2020 Jan 18. pii: S2152-2650(20)30012-4. PMID: 32067953
3. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3. PMID: 27713092; PMCID: PMC6020045.
4. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. *Blood*. 2010 Aug 26; 116(8):1197-1204. PMID: 20439623
5. Leger KJ, et al. Lifestyle factors and subsequent ischemia heart disease risk after hematopoietic cell transplantation. *Cancer*. 2018 Apr 1; 124(7):1507-1515. PMID: 29315507

6. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft *Versus* Host Disease: A Comprehensive Review. *Anticancer Res.* 2017 Apr;37(4):1547-1555. doi: 10.21873/anticancer.11483. PMID: 28373413.
7. Tichelli A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood.* 2007 Nov 1; 110(9):3463-3471. PMID: 17664354
8. Tichelli A, Gratwohl A. Vascular endothelium as “novel” target of graft-versus-host disease. *Best Pract Res Clin Haematol.* 2008 Jun; 21(2):139-148. PMID: 18503982

## **Advanced Heart Failure in Cancer Survivors**

1. Araujo-Gutierrez R, et al. Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. *Cardiooncology.* 2018 Mar 20;4:3. PMID: 32154004
2. Barrett CD, et al. Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. *JACC Heart Fail.* 2020 May 4:S2213-1779(20)30075-5. PMID: 32387068
3. Bianco CM, et al. Advanced heart failure therapies for cancer therapeutics-related cardiac dysfunction. *Heart Fail Clin.* 2017 Apr; 13(2):327-336. PMID: 28279418
4. Lenneman AJ, et al. Heart transplant survival outcomes for Adriamycin-dilated cardiomyopathy. *Am J Cardiol.* 2013 Feb 15; 111(4):609-12. PMID: 23195041
5. Oliveira GH, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant.* 2012 Aug; 31(8):805-810. PMID: 22551930
6. Oliveira GH, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol.* 2014 Jan 28; 63(3):240-248. PMID: 24161324
7. Trachtenberg BH, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. *Am J Transplant.* 2019 Oct;19(10):2900-2909. PMID: 31152491

## **Malignant Pericardial Effusion**

1. Kaira K, et al. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. *Jpn J Clin Oncol.* 2005 Feb; 35(2):57-60. PMID: 15709087
2. El Haddad D, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. *J Am Coll Cardiol.* 2016 Sep 8; 66(10):1119-1128. PMID: 26337990
3. Prabhakar Y, et al. Pericardial decompression syndrome: a comprehensive review. *World J Cardiol.* 2019 Dec 26; 11(12):282-291. PMID: 31908728

## Carcinoid Heart Disease

1. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. *Circulation*. 2007 Dec 11;116(24):2860-5. doi: 10.1161/CIRCULATIONAHA.107.701367. PMID: 18071089.
2. Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, Cuthbertson DJ, Dobson R, Grozinsky-Glasberg S, Steeds RP, Dreyfus G, Pellikka PA, Toumpanakis C. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. *J Am Coll Cardiol*. 2017 Mar 14;69(10):1288-1304. doi: 10.1016/j.jacc.2016.12.030. PMID: 28279296.
3. Manoly I, McAnelly SL, Sriskandarajah S, McLaughlin KE. Prognosis of patients with carcinoid heart disease after valvular surgery. *Interact Cardiovasc Thorac Surg*. 2014 Aug;19(2):302-5. doi: 10.1093/icvts/ivu146. Epub 2014 May 8. PMID: 24812331.
4. Warner RRP, Castillo JG. Carcinoid Heart Disease: The Challenge of the Unknown Known. *J Am Coll Cardiol*. 2015 Nov 17;66(20):2197-2200. doi: 10.1016/j.jacc.2015.05.086. PMID: 26564597.

## Cardiac Tumors

1. Lee E, Mahani MG, Lu JC, Dorfman AL, Srinivasan A, Agarwal PP. Primary cardiac tumors associated with genetic syndromes: a comprehensive review. *Pediatr Radiol*. 2018 Feb;48(2):156-164. doi: 10.1007/s00247-017-4027-2. Epub 2017 Dec 6. PMID: 29214333.
2. Maleszewski JJ, et al. Neoplasia and the heart: pathological review of effects with clinical and radiological correlation. *J Am Coll Cardiol*. 2018 Jul 10; 72(2):202-227. PMID: 29976295
3. Maleszewski JJ, et al. Pathology, imaging, and treatment of cardiac tumours. *Nat Rev Cardiol*. 2017 Sep; 14(9):536-549. PMID: 28436488
4. Sultan I, Bianco V, Habberthuer A, Kilic A, Gleason TG, Aranda-Michel E, Harinstein ME, Martinez-Meehan D, Arnaoutakis G, Okusanya O. Long-Term Outcomes of Primary Cardiac Malignancies: Multi-Institutional Results From the National Cancer Database. *J Am Coll Cardiol*. 2020 May 12;75(18):2338-2347. doi: 10.1016/j.jacc.2020.03.041. PMID: 32381166.

## Chimeric Antigen Receptor T-Cell Therapy

1. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). *J Am Coll Cardiol*. 2019 Dec 24;74(25):3099-3108. doi: 10.1016/j.jacc.2019.10.038. PMID: 31856966; PMCID: PMC6938409.
2. Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM, Yang EH, Zaha V, Barac A, Liu JE. Chimeric Antigen Receptor T-



- Cell Therapy for Cancer and Heart: JACC Council Perspectives. *J Am Coll Cardiol*. 2019 Dec 24;74(25):3153-3163. doi: 10.1016/j.jacc.2019.10.049. PMID: 31856973.
3. Ghosh AK, et al. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? *J Am Coll Cardiol CardioOnc*. 2020 Mar; 2:97-109. DOI: 10.1016/j.jacc.2020.02.011
  4. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum in: *Blood*. 2015 Aug 20;126(8):1048. Dosage error in article text. Erratum in: *Blood*. 2016 Sep 15;128(11):1533. PMID: 24876563; PMCID: PMC4093680.

## Electrophysiology and Cardio-Oncology

1. Brouillard É, Chamula M, Lavoie C, Varfalvy N, Archambault L. Radiation Therapy-Induced Dysfunction in Cardiovascular Implantable Electronic Devices. *Pract Radiat Oncol*. 2019 Jul-Aug;9(4):266-273. doi: 10.1016/j.prro.2019.03.003. Epub 2019 Mar 26. PMID: 30922971.
2. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke GD, Dickfeld TL, Froelich JW, Grant J, Hayes DL, Heidbuchel H, Idriss SF, Kanal E, Lampert R, Machado CE, Mandrola JM, Nazarian S, Patton KK, Rozner MA, Russo RJ, Shen WK, Shinbane JS, Teo WS, Uribe W, Verma A, Wilkoff BL, Woodard PK. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. *Heart Rhythm*. 2017 Jul;14(7):e97-e153. doi: 10.1016/j.hrthm.2017.04.025. Epub 2017 May 11. PMID: 28502708.
3. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. *J Am Heart Assoc*. 2017 Dec 7;6(12):e007724. doi: 10.1161/JAHA.117.007724. PMID: 29217664; PMCID: PMC5779062.
4. Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, Curcio TJ, Feldman EJ, Kligfield PD. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. *J Clin Oncol*. 2014 Nov 20;32(33):3723-8. doi: 10.1200/JCO.2013.51.2913. Epub 2014 Sep 22. PMID: 25245447.
5. Viganego F, Singh R, Fradley MG. Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation. *Curr Cardiol Rep*. 2016 Jun;18(6):52. doi: 10.1007/s11886-016-0730-0. PMID: 27108362.
6. Yeung C, Hazim B, Campbell D, Gooding J, Li SX, Tam HK, Hopman WM, Chacko S, Redfearn DP, Simpson C, Abdollah H, Baranchuk A. Radiotherapy for patients with cardiovascular implantable electronic devices: an 11-year experience. *J Interv Card Electrophysiol*. 2019 Sep;55(3):333-341. doi: 10.1007/s10840-018-0506-0. Epub 2019 Jan 3. PMID: 30603854.